Report Publication Announcement • Jan 4, 2017
Report Publication Announcement
Open in ViewerOpens in native device viewer
Marseille, France, January 4, 2017
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at four upcoming investor conferences in Q1 2017, where Innate Pharma's management team, including Mondher Mahjoubi, the newly appointed Chief Executive Officer and Chairman of Innate Pharma's Executive Board, will provide an overview of the Company.
The four investor conferences in Q1 2017 are:
Innate Pharma is committed to meet on a regular basis with the financial community. All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company's website in the Investors' section (http://www.innate-pharma.com/en/investors).
Innate Pharma S.A. is a clinical-stage biotechnology company with a focus on discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients.
Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells.
The Company's aim is to become a commercial stage biopharmaceutical company in the area of immunotherapy and focused on serious unmet medical needs in cancer. Innate Pharma has pioneered the discovery and development of checkpoint inhibitors to activate the innate immune system. Innate Pharma's innovative approach has resulted in three first-in-class, clinical-stage antibodies targeting natural killer cell receptors that may address a broad range of solid and hematological cancer indications as well as additional preclinical product candidates and technologies. Targeting receptors involved in innate immunity also creates opportunities for the Company to develop therapies for inflammatory diseases.
The Company's expertise and understanding of natural killer cell biology have enabled it to enter into major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi.
Based in Marseille, France, Innate Pharma has more than 150 employees and is listed on Euronext Paris.
Learn more about Innate Pharma at www.innate-pharma.com.
Practical Information about Innate Pharma shares:
| ISIN code | |
|---|---|
| Ticker code | IPH |
FR0010331421
Disclaimer:
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
Laure-Hélène Mercier Chief Financial Officer Tel.: +33 (0)4 30 30 30 87
Marie Puvieux Mob: +33 (0)6 10 54 36 72 [email protected]
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Hendrik Thys
Tel.: +44 (0)20 3709 5700
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.